Quantcast

Latest Exenatide Stories

2014-03-10 23:27:46

National network of lawyers continues offer of complimentary consultations to consumers seeking compensation in lawsuits alleging links between diabetes medications Byetta, Januvia, Janumet and Victoza and pancreatic cancer. San Diego, CA (PRWEB) March 10, 2014 http://www.resource4thepeople.com/defectivedrugs/byetta.html Resource4thePeople announced today its latest update for consumers following allegations in lawsuits* claiming that the use of the diabetes medication Byetta and other...

2014-03-03 08:32:04

Podium Presentation Highlighting Safety and Efficacy Data to be Presented by the Company's CSO, Dr. Miriam Kidron JERUSALEM, March 3, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it will be presenting detailed results from its recently completed Phase 2a FDA trial on ORMD-0801, its orally ingestible insulin capsule...

2014-03-01 23:01:16

The Firm is actively investigating Byetta lawsuit claims on behalf of diabetics who may have been diagnosed with pancreatitis, pancreatic cancer or thyroid cancer after taking the medication. New York, New York (PRWEB) March 01, 2014 The federal litigation of Byetta lawsuits (http://www.byettalawsuit.com/) and other claims involving similar Type 2 diabetes drugs has grown to include more than 300 cases, Bernstein Liebhard LLP reports. According to a Case List updated February 19th by the...

2014-02-27 23:37:06

National network of lawyers continues offer of complimentary consultations to consumers seeking compensation in lawsuits alleging links between diabetes medications Januvia, Byetta, Janumet and Victoza and pancreatic cancer. San Diego, CA (PRWEB) February 27, 2014 http://www.resource4thepeople.com/defectivedrugs/januvia.html Resource4thePeople announced today its latest update for consumers following allegations in lawsuits* claiming that the use of the diabetes medications Januvia,...

2014-02-26 08:30:09

- Smith takes-on innovative CXO role to optimize customer experiences and consistently deliver the best possible outcomes for patients, payors and providers - BOSTON, Feb. 26, 2014 /PRNewswire/ -- Intarcia Therapeutics, Inc. today formally announced the appointment of Jay Smith as Head of Customer Experience & Outcomes (CXO), an officer level position for which there is no precedent or analogue in the Bio-Pharma industry. The role focuses on one of the highest priorities within...

2014-02-25 08:31:50

Once-Weekly Dulaglutide Hits Primary Endpoint in Sixth Consecutive AWARD Trial INDIANAPOLIS, Feb. 25, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive top-line results of the sixth AWARD (Assessment of Weekly AdministRation of LY2189265 in Diabetes) trial for once-weekly dulaglutide, an investigational, long-acting glucagon-like peptide 1 (GLP-1) receptor agonist being studied as a treatment for type 2 diabetes. In the AWARD-6 study, once-weekly...

2014-02-22 23:01:04

The Firm is evaluating Byetta lawsuits on behalf of patients who allegedly developed pancreatic cancer, pancreatitis, or thyroid cancer due to their use of the Type 2 diabetes medication. New York, New York (PRWEB) February 22, 2014 A Byetta lawsuit (http://www.byettalawsuit.com) Plaintiff has withdrawn her motion seeking the consolidation of all federal claims involving allegations that the Type 2 diabetes drug caused patients to develop thyroid cancer, Bernstein Liebhard LLP reports....

2014-02-17 23:03:29

The Firm is investigating Byetta lawsuits on behalf of individuals who developed pancreatic cancer, thyroid cancer or pancreatitis, allegedly due to their use of the Type 2 diabetes medication. New York, New York (PRWEB) February 17, 2014 The federal court overseeing dozens of Byetta lawsuits (http://www.byettalawsuit.com) and other product liability claims involving Type 2 diabetes drugs known as incretin mimetics is now considering proposals for the case management of the...

2014-02-13 23:01:43

The Firm is evaluating Byetta lawsuits and other legal claims on behalf of individuals who allegedly developed pancreatic cancer, pancreatitis, and thyroid cancer due their use of incretin mimetic medications used to treat Type 2 diabetes. New York, New York (PRWEB) February 13, 2014 As Byetta lawsuits (http://www.byettalawsuit.com) and other legal claims involving incretin mimetic drugs continue to move forward in U.S. courts, Bernstein Liebhard LLP notes that U.S. health regulators...

2014-02-10 12:25:17

JERUSALEM, Feb. 10, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has submitted a protocol to the U.S. Food and Drug Administration (FDA) to initiate a Phase 2a trial of its orally ingestible insulin capsule, ORMD 0801, for type 1 diabetes. The protocol was submitted under Oramed's existing IND for ORMD-0801 to include both...


Latest Exenatide Reference Libraries

36_67c6fec75293d7e1e91a0c52aa692cf7
2005-06-22 14:17:05

The Gila monster (Heloderma suspectum) is one of the two known species of venomous lizards. This lizard lives in the deserts of the southwestern USA and northwestern Mexico. It is a heavy, slow moving lizard and can measure up to 2 feet (60 cm) in length. Its skin has the appearance of beads in the colors black, pink, orange, and yellow, laid down in intricate patterns across the animal's body. Unlike a snake, the Gila monster envenomates its victim through grooves in the teeth of its...

More Articles (1 articles) »
Word of the Day
out-herod
  • In the phrase to out-herod Herod, to be more violent than Herod (as represented in the old mystery plays); hence, to exceed in any excess of evil.
Herod refers to 'Herod the Great,' a Roman client king and 'a madman who murdered his own family and a great many rabbis.' According to the OED, the term is 'chiefly with allusion to Shakespeare's use' in Hamlet.
Related